Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review

Abstract

Background:Ovarian cancer is the most lethal gynaecological cancer. Progression-free and overall survival is significantly related to surgical success and residual disease volume. It is unclear whether this survival advantage is due to an intrinsic biological element of the tumour cells which enables successful surgery and improved prognosis, or alternatively the number of tumour sustaining cells remaining irrespective of differences in biology.Methods:A systematic review of the literature was performed identifying studies that have investigated the association between biomarkers and surgical outcomes. We attempted validation of these results using The Cancer Genome Atlas ovarian cancer data sets.Results:Thirty studies were identified of which sixteen determined protein expression, eight gene expression and one DNA methylation in association with surgical debulking. Individualised linear models adjusting for batch, stage and age identified only expression of the genes MTDH and insulin-like growth factor-1 receptor (IGF1R) to be significantly associated with debulking surgery (P<0.05, false discovery rate (FDR)<5%), although in the case of IGF1R this was in the opposite direction to previous findings.Conclusion:The majority of studies are limited by design, include heterogeneous samples and lack adjustment for major confounding factors. High quality detailed clinical annotations should be routinely collected in future to more accurately evaluate biomarkers of surgical outcome.

Optimizing the primary treatment of patients with advanced ovarian cancer

“…предложи-ли панель из 32 генов, которая может прогнозировать успех первичной циторедукции с точностью 72,7 % [37]. Несмотря на научный интерес, экономическая эффек-тивность и проблемы имплементации таких моделей представляют еще бóльшую сложность, а полученные предварительные оптимистичные результаты могут быть подвержены влиянию целого ряда факторов, в первую очередь -особенностей хирургических подходов [38].…”

AEG-1/MTDH/LYRIC, the Beginning

“…Recent studies have also investigated the expression of AEG-1/MTDH/LYRIC in ovarian cancer, the most lethal gynecological cancer (Borley, Wilhelm-Benartzi, Brown, & Ghaem-Maghami, 2012; Li et al, 2012; Li, Liu, et al, 2011; Meng, Luo, Ma, Hu, & Lou, 2011). Immunohistochemical staining of AEG-1/MTDH/LYRIC in 81 ovarian cancer patient tissues revealed that high expression of AEG-1/MTDH/LYRIC was detected in 66.7% of ovarian cancer patients in association with clinicopathologic features of the cancer and poor overall survival of the patients when compared with patients with lower expression of AEG-1/MTDH/LYRIC (Meng et al, 2011).…”

3‑Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer

“…Briefly, the cells were plated at a density of 6x10 5 cells/well in 6-well plates and allowed to grow overnight at 37˚C. In total, 2 µg of each plasmid DNA and 5 µl Lipofectamine 2000 were diluted separately in Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) to a total volume of 250 µl.…”

“…Furthermore, recurrence or metastasis occurs in >75% of patients within the first 2 years following initial treatment (3,4). In the majority of patients, initial responses can be achieved with debulking surgery and treatment with taxanes in combination with platinum-based chemotherapy; however, >75% of those responders eventually relapse, resulting in chemoresistant and fatal disease (5,6).…”